newsfilter
← Latest News
GlobeNewswire·

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

  • Tiziana Life Sciences, Ltd. announced the withdrawal of its proposed public offering of common shares due to current market conditions.
  • The company is a clinical-stage biopharmaceutical firm developing immunomodulation therapies using alternative drug delivery routes.
  • Tiziana's lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody that is the only one of its kind in clinical development.
  • The nasal delivery approach for immunotherapy aims to improve efficacy, safety, & tolerability compared to intravenous administration.
  • In an open-label Expanded Access Program, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis showed improvement or disease stability within six months.
  • Intranasal foralumab is currently being evaluated in a Phase 2a randomized, double-blind, placebo-controlled, multicenter trial for non-active secondary progressive multiple sclerosis.
  • Tiziana holds patents for its alternative route technology, with several applications pending to support a broad pipeline.
  • The press release includes standard forward-looking statements warning that actual results may differ from forecasts due to risks & uncertainties.